CRISPR-Cas13d: Transgenic zebrafish lines toknockdown mRNA

CRISPR-Cas13d:转基因斑马鱼系敲除 mRNA

基本信息

  • 批准号:
    10598232
  • 负责人:
  • 金额:
    $ 20.63万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-12-15 至 2024-11-30
  • 项目状态:
    已结题

项目摘要

Project Summary Determining the function of genes is fundamental for understanding vertebrate development, regulatory mechanisms and human diseases. Genome editing technologies, such CRISPR-Cas9, have allowed associating specific phenotypes to permanent gene alteration. However, some key technical and conceptual issues remain problematic in vertebrates, particularly in aquatic model organisms such zebrafish. For example, the maternally provided mRNA can rescue the phenotype of homozygous mutants; genotyping steps are tedious; and long non- coding RNA, lethal or tissue/temporal genes are difficult to study using DNA manipulation as well as complex genomic loci. Complementary ‘knock-down’ approaches are invaluable tools to circumvent some of these problems, however, there was no systematic tool to knockdown mRNAs in zebrafish or other teleost fish. Our long-term goal is to unravel the function of genes related to regulatory mechanisms, development, and human diseases. Our recent publication demonstrates that injection of the CRISPR-RfxCas13d system into vertebrate embryos provides a robust and cost-effective technology to systematically disrupt gene function. However, the injection of this system only provides transient knockdown for ~3 days. Therefore, the central goal of the proposal is to transfer the CRISPR-RfxCas13d technology from being injected into vertebrate embryos, to being endogenously expressed through transgenesis. We propose that the development of a repertoire transgenic zebrafish expressing the RfxCas13d enzyme (ubiquitous and tissues-specific) and guideRNA would facilitate rapid and vigorous investigation into gene functions. Our preliminary data indicate that transgenic expression of RfxCas13d in zebrafish is functional and not toxic. The objectives are: 1) Define the optimal system to knockdown mRNA expression in CRISPR-RfxCas13d transgenic zebrafish. 2) Knockdown mRNA expression in a tissue-specific manner using specific transgenic lines. This proposal is conceptually innovative as it is based on the exploration of a novel technique, CRISPR-RfxCas13d, to knockdown mRNA in a tissue-specific manner in zebrafish. This approach has never been done in vertebrate model systems where RNAi does not work. The outcomes of this project will be the first transgenic system to dissect and study gene function by knocking down mRNA expression in zebrafish. Our approach will help the scientific community investigate gene function in a faster and tissue-temporal specific manner, as well as answering questions that are very challenging to address by current methodologies, such as the function of non-coding RNAs or phenotypes caused by multiple genes. Moreover, by following the guidelines we will optimize through this project, researchers may produce a whole guideRNA collection, targeting all genes, which should be available for anyone to order to address their individual research questions. Finally, as we have successfully implemented the CRISPR-Cas13d system by injection in other organisms such as medaka, killifish, and mouse embryos, our work described in this proposal may serve as the foundation for transferring this efficient knockdown technology into a range of other species.
项目摘要 确定基因的功能是理解脊椎动物发育,调节性的基础 机制和人类疾病。 但是,某些关键的技术和概念性的发源 脊椎动物中有问题,尤其是水生生物,例如斑马鱼。 预期的mRNA可以挽救纯合突变体的表型; 编码RNA,致命或组织/颞基因是使用DNA操纵以及复合物研究的 基因组基因座。 但是,问题不是在斑马鱼或其他硬骨鱼中敲除mRNA的系统性工具。 我们的长期目标是阐明与调节机制,发展和和 人类疾病。我们最近出版 脊椎动物的胚胎为有系统的破坏基因功能提供了强大且具有成本效益的技术。 霍弗(Howver),系统的注入仅提供3天的转移敲低 该提案的内容是将CRISPR-RFXCAS13D技术从注射到Bertebrate Embryos,到 通过转基因表达。 表达RFXCAS13D酶的转基因斑马鱼(普遍和组织特异性)和Guiderna将 促进对基因功能的快速和剧烈研究。 斑马鱼中RFXCAS13D的表达是功能性的,而不是有毒的。 在CRISPR-RFXCAS13D转基因斑马鱼中敲低mRNA表达。 使用特定的转基因线以特异性方式进行概念性创新 关于新型技术的验证CRISPR-RFXCAS13D,以特定于组织的方式敲除mRNA 在斑马鱼中。 该项目的结果将是第一个通过知道门徒的转基因系统,也是最佳基因功能。 斑马鱼中的mRNA表达。 以更快和组织的特定方式,以及令人难以置信的问题,这些问题非常具有挑战性 通过当前方法的解决 此外,通过遵循指南,我们将通过该项目进行优化,研究人员可能会产生 整个Guiderna收集,以所有基因为目标,任何人都应该订购以解决 他们的个人研究问题。 通过注射Medaka,Killifish和Mouse Embryos等其他生物,我们在此提案中描述了我们的工作 可以作为将造成的敲低技术转移到其他物种的基础。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ariel Bazzini其他文献

Ariel Bazzini的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ariel Bazzini', 18)}}的其他基金

Small translated ORFs in the 3'UTR enhance translation in vertebrates
3UTR 中的小翻译 ORF 增强脊椎动物的翻译
  • 批准号:
    10534126
  • 财政年份:
    2020
  • 资助金额:
    $ 20.63万
  • 项目类别:
Small translated ORFs in the 3'UTR enhance translation in vertebrates
3UTR 中的小翻译 ORF 增强脊椎动物的翻译
  • 批准号:
    10308512
  • 财政年份:
    2020
  • 资助金额:
    $ 20.63万
  • 项目类别:

相似国自然基金

TRIM25介导的泛素化及ISGylation通过选择性剪接和糖代谢调控髓细胞分化
  • 批准号:
    82370111
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
PRMT5选择性剪接异构体通过甲基化PDCD4调控肝癌辐射敏感性的机制研究
  • 批准号:
    82304081
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
ac4C乙酰化修饰的HnRNP L选择性剪接EIF4G1调控糖代谢重编程介导前列腺癌免疫检查点阻断治疗无应答的机制研究
  • 批准号:
    82303784
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
由CathepsinH介导的YAP选择性剪接在辐射诱导细胞死亡及辐射敏感性中的作用
  • 批准号:
    82373527
  • 批准年份:
    2023
  • 资助金额:
    48 万元
  • 项目类别:
    面上项目
拟南芥剪接因子SR蛋白通过选择性剪接调控获得性耐热的机理研究
  • 批准号:
    32300247
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Pharmacodynamic Biomarker of Myotonic Dystrophy
强直性肌营养不良的药效生物标志物
  • 批准号:
    10651049
  • 财政年份:
    2023
  • 资助金额:
    $ 20.63万
  • 项目类别:
A Novel Long Noncoding RNA Associated with Systemic Lupus Erythematosus Pathogenesis
一种与系统性红斑狼疮发病机制相关的新型长非编码RNA
  • 批准号:
    10725130
  • 财政年份:
    2022
  • 资助金额:
    $ 20.63万
  • 项目类别:
LNCRNA REGULATION OF GENE EXPRESSION & BEHAVIOR
LNCRNA 基因表达调控
  • 批准号:
    10706509
  • 财政年份:
    2022
  • 资助金额:
    $ 20.63万
  • 项目类别:
Hereditary Genetics of Hepatocellular Carcinoma
肝细胞癌的遗传遗传学
  • 批准号:
    10598810
  • 财政年份:
    2022
  • 资助金额:
    $ 20.63万
  • 项目类别:
A Novel Long Noncoding RNA Associated with Systemic Lupus Erythematosus Pathogenesis
一种与系统性红斑狼疮发病机制相关的新型长非编码RNA
  • 批准号:
    10537564
  • 财政年份:
    2022
  • 资助金额:
    $ 20.63万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了